Ernexa Therapeutics
Open
$6.43
Prev. Close
$6.43
High
$6.43
Low
$6.40
Market Snapshot
$7.11M
-0.6
-48.34
$582K
6
Ernexa Therapeutics, Inc. engages in the provision of cell engineering therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 5 full-time employees. The firm is focused on using cutting-edge gene-editing tools to deliver safe off-the-shelf cell therapies for the treatment of advanced solid tumors. Its Pipeline includes ERNA-101, and ERNA-102. Its core technology utilizes engineer allogenic-induced pluripotent stem cells (iPSCs) to express genes of interest and to efficiently differentiate these cells into mesenchymal stem cells (iMSCs). The firm seeks to capitalize on the intrinsic tumor-homing ability of MSCs to slip through the tumor’s defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment (TME), thus unleashing potent anti-cancer immune responses. The firm is focused on developing iPSC-derived iMSC that express critical factors, such as pro-inflammatory cytokines.
Ernexa Therapeutics, Inc. engages in the provision of cell engineering therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 5 full-time employees. The firm is focused on using cutting-edge gene-editing tools to deliver safe off-the-shelf cell therapies for the treatment of advanced solid tumors. Its Pipeline includes ERNA-101, and ERNA-102. Its core technology utilizes engineer allogenic-induced pluripotent stem cells (iPSCs) to express genes of interest and to efficiently differentiate these cells into mesenchymal stem cells (iMSCs). The firm seeks to capitalize on the intrinsic tumor-homing ability of MSCs to slip through the tumor’s defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment (TME), thus unleashing potent anti-cancer immune responses. The firm is focused on developing iPSC-derived iMSC that express critical factors, such as pro-inflammatory cytokines.
Recently from Cashu
Ernexa Therapeutics Unveils Promising Combination Therapy for Enhanced Ovarian Cancer Treatment
Ernexa Therapeutics has advanced the field of ovarian cancer treatment with their recent research findings regarding a combination therapy that significantly enhances treatment efficacy compared to st…
Ernexa Therapeutics Advances Pipeline with Acquisition of Promising Drug Candidate ERX-109
Ernexa Therapeutics Expands its Pipeline with Promising New Drug Candidate Ernexa Therapeutics, a biopharmaceutical company focused on developing innovative therapies for rare diseases, announces the…
Ernexa Therapeutics Launches Innovative Products, Boosts Revenue and Expands Internationally
Ernexa Therapeutics Expands Horizons with Innovative Product Launch Ernexa Therapeutics is making significant strides in the biopharmaceutical industry, particularly with its recent launch of a new pr…
It seems like you haven't provided the content to summarize. Please share the text you'd like me to summarize, and I'll help you create a title!
Please provide the content that you want summarized, and I'll be happy to assist you with that.